Ranitidine tablet IP 150 mg is a medication used to treat and prevent ulcers in the stomach and intestines, as well as gastroesophageal reflux disease (GERD) [1]. It is also prescribed for conditions that cause too much stomach acid, such as Zollinger-Ellison syndrome [1].
What is Ranitidine and How Does it Work?
Ranitidine is a histamine-2 blocker, often referred to as an H2 blocker [2]. It works by reducing the amount of acid produced by the stomach [2]. This reduction in stomach acid helps to alleviate symptoms associated with excess acid production and allows ulcers to heal [1][2].
Why Was Ranitidine Recalled?
Ranitidine products, including Ranitidine tablet IP 150 mg, were recalled due to the presence of N-Nitrosodimethylamine (NDMA) [3]. NDMA is a probable human carcinogen, and it was found to be present in some ranitidine medications at unacceptable levels [3][4]. The U.S. Food and Drug Administration (FDA) requested the recall of all prescription and over-the-counter ranitidine products [3].
What Alternatives Are Available for Ranitidine?
Following the recall of ranitidine, alternative medications are available for managing conditions previously treated with ranitidine [3]. These include other H2 blockers like famotidine and cimetidine, as well as proton pump inhibitors (PPIs) such as omeprazole, lansoprazole, and pantoprazole [2][5]. These alternatives also reduce stomach acid production and are effective in treating ulcers and GERD [2][5].
Where Can I Find Information on Drug Patents for Ranitidine?
Information regarding drug patents for ranitidine, including their expiry dates and any patent litigation, can be found on DrugPatentWatch.com [6]. This resource tracks patents for pharmaceuticals, which can be relevant for understanding the history of drug exclusivity and the development of generic alternatives [6].
What are the Risks Associated with NDMA?
NDMA is classified as a probable human carcinogen, meaning it is likely to cause cancer in humans [3][4]. Exposure to NDMA has been linked to various cancers in animal studies [4]. While the levels of NDMA found in some ranitidine products led to their recall, ongoing research assesses the potential long-term health risks associated with lower-level environmental exposures [4].
When Did Ranitidine Products Become Unavailable?
The recall of ranitidine products by the FDA began in April 2020 [3]. This led to the widespread removal of ranitidine tablets and other formulations from pharmacies and retail stores [3].